
==== Front
Pharmacy (Basel)
Pharmacy (Basel)
pharmacy
Pharmacy
2226-4787
MDPI

10.3390/pharmacy12050132
pharmacy-12-00132
Article
Effective Supply Chain Strategies in Addressing Demand and Supply Uncertainty: A Case Study of Ethiopian Pharmaceutical Supply Services
https://orcid.org/0000-0001-8079-9550
Bilal Arebu Issa Methodology Software Validation Formal analysis Investigation Data curation Writing – original draft Writing – review & editing Visualization Project administration 1*
Bititci Umit Sezer Conceptualization Methodology Validation Resources Writing – review & editing Supervision Funding acquisition 2
Fenta Teferi Gedif Conceptualization Methodology Validation Resources Writing – review & editing Supervision Funding acquisition 1
Willey Vincent J. Academic Editor
1 Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia
2 Edinburgh Business School, Heriot Watt University, Edinburgh EH14 4AS, UK
* Correspondence: arebu.issa@aau.edu.et; Tel.: +251-913490403
28 8 2024
10 2024
12 5 13220 6 2024
09 8 2024
17 8 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Background: Ensuring the consistent availability of essential medicines is crucial for effective healthcare systems. However, Ethiopian public health facilities have faced frequent stockouts of crucial medications, highlighting systemic challenges such as inadequate forecasting, prolonged procurement processes, a disjointed distribution system, suboptimal data quality, and a shortage of trained professionals. This study focuses on the Ethiopian Pharmaceutical Supply Services (EPSS), known for its highly unstable and volatile supply chain, aiming to identify risks and mitigation strategies. Methods: Using a mixed-method approach involving surveys and interviews, the research investigates successful and less successful strategies, key success factors, and barriers related to pharmaceutical shortages. Results: Proactive measures such as communication, stock assessment, supervision, and streamlined procurement are emphasized as vital in mitigating disruptions, while reactive strategies like safety stock may lack long-term efficacy. The study highlights the importance of aligning supply chain strategies with product uncertainties, fostering collaboration, and employing flexible designs for resilience. Managerial implications stress the need for responsive structures that integrate data quality, technology, and visibility. Conclusions: This study contributes by exploring proactive and reactive strategies, elucidating key success factors for overcoming shortages in countries with unstable supply chains, and offering actionable steps for enhancing supply chain resilience. Embracing uncertainty and implementing proactive measures can help navigate volatile environments, thereby enhancing competitiveness and sustainability.

demand
pharmaceutical supply chain
proactive
reactive
strategies
supply
Kühne Foundation0011 This research was funded by the PhD Student Research Grant from LEARN Logistics gGmbH by Kühne Foundation. The grant number 0011.
==== Body
pmc1. Introduction

Universal access to essential medicines is crucial for effective healthcare systems, yet equitable availability remains a global challenge [1,2]. Many nations, particularly in Africa and Asia, struggle with access due to unaffordability and supply chain inefficiencies [3,4]. Drug shortages also impact developed countries like the U.S. and Europe, affecting healthcare quality and patient care [5,6]. These shortages, caused by supply chain disruptions, have financial and patient care consequences [5,7,8].

Factors such as globalization, manufacturing issues, natural disasters, pandemics, and regulatory requirements contribute to medicine shortages [8,9]. Supply chain complexities introduce additional challenges like demand variations and resource limitations [10]. Recent disruptions, including material cost increases [11], demand variations due to the COVID-19 pandemic [12], and supply chain interruptions, have exposed the vulnerability of supply chains [13,14,15,16]. These challenges necessitate a reevaluation of supply chain strategies to enhance resilience and adaptability [17,18].

Inaccurate demand forecasting increases healthcare costs and inefficiencies, affecting drug therapy and patient safety [19,20,21,22,23,24]. A robust supply chain strategy integrates suppliers, manufacturers, and distribution mechanisms to optimize resources and service levels [24]. Addressing shortages, especially in low-income countries, involves managing stock use restrictions, efficient redistribution, and enhancing stakeholder communication [25]. Persistent research gaps in low- and middle-income countries highlight the need for collaborative efforts to tackle this challenge.

An efficient supply chain is integral to organizational success, particularly in healthcare, consumer goods, and agriculture, where shortages can have costly consequences [26,27]. Managing supply and demand uncertainty remains a persistent challenge [28]. Fisher (1997) categorized supply chains into efficient and responsive types based on demand predictability, while Lee (2002) extended this framework to include supply uncertainties. Effective management of these uncertainties involves mechanisms to cope with them and meet customer demands efficiently [29,30].

As supply chain management becomes increasingly complex due to changing customer demands, disruptions, and natural disasters, recent global economic turbulence emphasizes the urgency for resilient and sustainable strategies. Demand uncertainty, arising from factors like seasonal fluctuations and economic conditions, necessitates a flexible supply chain. Supply uncertainty poses challenges such as supplier unreliability, communication issues, and quality concerns. Effective management requires robust supplier relationships, rapid onboarding, and harmonized communication. Operational uncertainties, including transportation delays and production disruptions, impact the supply chain, requiring real-time tracking and effective inventory management. The COVID-19 pandemic and geopolitical events, such as Brexit and conflicts in Ukraine, Gaza, and Yemen, have amplified global supply chain disruptions. Issues like chip shortages and shipping delays underscore the need for strategic supply chain planning and resilience. Geopolitical events disrupt international supply chains, highlighting their vulnerability. The disruption emphasizes the challenges of internal supply chain volatility, necessitating strategies to transform volatility into opportunities.

In Ethiopia, the pharmaceutical supply chain has evolved with EPSS and the Pharmaceutical Logistics Master Plan but still faces issues like stock-outs and wastage [31,32,33]. Comprehensive research is needed to develop effective mitigation strategies, especially in resource-limited settings. This paper aims to identify risks in the EPSS supply chain and strategies to mitigate drug shortages, using literature reviews, surveys, and interviews to guide effective supply chain strategies.

2. Literature Review

Our work relates to several streams of literature, including relevant studies that focus on pharmaceutical drug shortages, supply chain risks, factors that contribute to drug product shortages, challenges in the Ethiopian Pharmaceutical Supply Services, and supply chain strategies during demand uncertainties in the pharmaceutical industry.

2.1. Drug Shortages Factors That Contribute to Drug Shortages

Drug shortages occur when the total supply of all clinically interchangeable versions of a regulated drug falls short of demand [34]. Despite increased research, reliable data to assess and combat medicine shortages globally remain insufficient [35,36]. In the U.S., medicine shortages have been tracked since the early 2000s but still persist [35,37]. The global rise in essential medicine shortages poses a significant challenge [35,38,39]. Unpredictable demand, limited planning resources, and organizational constraints exacerbate this issue [40]. Drug shortages significantly impact global healthcare, driven by multifaceted factors. These include non-traditional economics where patients lack control over prescriptions and limited transparency in manufacturing [41,42]. Medical supply chains face access, security, and traceability issues [40]. Manufacturing delays, capacity limits, and business decisions disrupt supply, alongside shortages in active pharmaceutical ingredients (APIs) and raw materials. Inefficient inventory practices and restricted distribution exacerbate the issue [39,43,44]. Additional challenges like single sourcing, global sourcing risks, minimal buffer stocks, and a focus on cost reduction increase vulnerabilities [45,46]. Supply chain risks from environmental, organizational, or network sources lead to chaos, inertia, and a lack of confidence [47,48,49]. Regulatory demands and market entry barriers further complicate the situation [35,44]. Understanding these factors is crucial for developing strategies to mitigate the impact of drug shortages on healthcare.

In Ethiopia, frequent stockouts of essential medicines worsen healthcare challenges [31,50]. Effective solutions are urgently needed to address these shortages. Understanding the definition, prevalence, and consequences of drug shortages is crucial for mitigating their impact on healthcare systems and patient well-being.

2.2. Supply Chain Risks

Organizations form interconnected networks, increasing interdependence and associated risks [51]. These complex supply chains span globally, with risks multiplying across components and processes [52,53]. Modern technology helps mitigate these risks through digitalization and data analytics [54]. Supply chain risks are categorized into demand risks, such as seasonal fluctuations, and supply risks, like manufacturing challenges [55]. Risks include delays, disruptions, forecast inaccuracies, and intellectual property breaches [56]. External risks stem from events like natural disasters, while internal risks arise from supply chain management [46]. Supply disruptions can lead to customer dissatisfaction, revenue loss, and safety concerns [45]. Understanding and mitigating these risks is crucial for maintaining a robust supply chain.

2.3. Challenges in the Ethiopian Pharmaceutical Supply Services

The Ethiopian Pharmaceutical Supply Services (EPSS) plays a vital role in providing affordable and reliable pharmaceuticals to public health facilities in Ethiopia. However, several challenges have hampered its ability to effectively manage drug shortages and ensure the availability of essential medications. One significant challenge faced by the EPSS is inaccurate drug forecasting. A study conducted within the EPSS [57] revealed that the mean percentage forecast error for program commodities stood at 27.8%. This error rate exceeds the acceptable threshold, which is 25% or less [58], and there are variations in forecast accuracy among individual items. For instance, forecast errors for HIV/AIDS and malaria commodities reached 31.71% and 37.25%, respectively, deviating from the expected range [57,59]. The EPSS encounters lengthy procurement lead times, with an average of 137.3 days and orders sometimes experiencing delays of up to 294 days. Such delays significantly impact drug availability. In addition, poor data quality and inaccurate and incomplete consumption reports from service delivery points have led to unacceptable forecasting errors. Coupled with communication and coordination challenges within the EPSS, these further exacerbate supply chain problems [60]. A study involving 40 health facilities in Ethiopia identified human resources, financial resources, infrastructure, and information technology challenges as key issues in pharmaceutical supply chain management [40].

The EPSS grapples with systemic weaknesses, including the absence of a robust system to manage its operations, weak demand planning, extended procurement lead times, inadequate medical equipment management, and a lack of emphasis on market shaping [19,61]. A SWOT analysis conducted in the EPSS unveiled several areas of concern, such as inadequate customer and stakeholder satisfaction, unsatisfactory supplier relationship management, inventory management challenges, weak distribution planning, and a deficient track and trace system. Furthermore, issues like the absence of a robust information system, inadequate financial sustainability planning, cash shortages, untrained staff, inefficient workforce utilization, and organizational culture problems have been identified [61].

In conclusion, the Ethiopian Pharmaceutical Supply Services faces multifaceted challenges that hinder its ability to effectively manage drug shortages and ensure drug availability. Addressing these challenges requires a comprehensive and coordinated effort to improve forecasting, streamline procurement processes, enhance data quality, and bolster the overall pharmaceutical supply chain management system.

2.4. Supply Chain Strategies

The pharmaceutical industry involves a range of entities including research-based multinationals, generic manufacturers, biotech startups, and specialized logistics providers [62]. Managing this complex supply chain is challenging due to factors like product diversity, short life cycles, outsourcing, technological advancements, and globalization [30]. Additionally, high costs, prolonged clinical trials, and uncertainties in demand and capacity planning further complicate the industry [63]. In low-income countries, ensuring the availability and affordability of essential medicines is crucial. Strategies such as limiting stock use, transparent redistribution, and proactive shortage management are employed [25]. Effective communication among regulatory bodies, harmonization, and robust reporting systems are essential for mitigating drug shortages [37,64]. Investments in research, policies, guidelines, education, and training are also necessary [25,38].

Supply chain strategies must account for demand and supply uncertainties. Fisher’s framework categorizes products as functional or innovative based on demand predictability and supply processes as stable or evolving [29]. For stable products, efficient supply chains focus on productivity and logistics optimization [30]. Innovative products require responsive strategies to adapt to changing demands [65]. Companies dealing with both innovative products and unstable supply processes must use a combination of risk-hedging and responsive strategies to manage uncertainties [30]. Global collaboration, particularly among low-income countries, is essential for developing effective mitigation strategies for drug shortages. International regulatory bodies should work together on a unified definition and global mitigation plan. Nationally, countries should establish proactive systems for drug shortage notification, reporting, and tracking. Policies should promote robust supply chains, encourage quality manufacturing systems, and prioritize the production of high-risk medicines. Training healthcare professionals and educating the public is also critical to minimize health-related consequences [25].

In conclusion, addressing demand uncertainties in the pharmaceutical industry requires a nuanced understanding of product characteristics, supply processes, and effective supply chain strategies. Also, it is clear that collaboration at both national and international levels is critical to mitigating the global issue of drug shortages across all economic levels (Table 1).

The aim of this study is to understand the risks in the EPSS supply chains and identify strategies that could be engaged to mitigate the risk of drug shortages. Thus, the specific research questions of this paper are:Which supply chain strategies, individually or in combination, provide an effective means for minimizing the drug shortages in Ethiopian Pharmaceutical Supply Services?

What strategies have been the least effective in reducing or eliminating supply chain disruptions?

What are the barriers that prohibit supply chain management strategies from becoming successful?

3. Research Method

3.1. Context

The Ethiopian Pharmaceutical Supply Services (EPSS) falls under the Ministry of Health, which is responsible for the forecasting, procurement, warehousing, and distribution of pharmaceuticals throughout the country. It has 19 branches, which are found in all regions of Ethiopia. The EPSS operates as a government agency under the Ministry of Health, tasked with centralizing the procurement and distribution of pharmaceuticals and medical supplies for the public health sector. It plays a crucial role in ensuring the availability and accessibility of essential medicines and medical products across the country.

The EPSS is entrusted with procuring pharmaceutical products and medical supplies through competitive bidding processes, aiming to secure high-quality products at reasonable prices. It maintains central medical stores strategically positioned throughout the country, acting as warehouses that manage and distribute the procured pharmaceuticals to regional and district health facilities. The EPSS places significant emphasis on improving supply chain management practices to reduce stock outs and minimize the wastage of pharmaceuticals. Through the use of information systems and logistics management tools, the agency strives to optimize inventory and enhance the efficiency of the distribution process.

Furthermore, the EPSS collaborates with the Ethiopian Food and Drug Authority (EFDA) to ensure that all procured medicines and medical supplies meet the required quality standards. The agency actively works towards enhancing access to essential medicines, particularly in underserved and remote areas, through its distribution networks and partnerships with health authorities and stakeholders. Additionally, the EPSS engages in collaboration with international organizations, donors, and development partners to strengthen its capacity and continually improve pharmaceutical supply chain practices.

3.2. Research Design

This study utilized a cross-sectional case study research design to assess the effectiveness of supply chain strategies employed to deal with drug shortages within the EPSS. The research was structured into two sequential parts, a survey and semi-structured interviews.

3.2.1. Part 1—Survey

The first part of the study comprised a survey that included socio demographic questions (such as years of experience in the sector, education level, and professions), as well as questions about supply chain strategies and their effectiveness. In this section, the respondents were presented with different supply chain strategies and asked to rate their effectiveness using a 5-point Likert scale, ranging from “highly effective” to “never effective”. The questionnaire, which is provided in Appendix A, was completed by 50 respondents with the demographic profile, as summarized in Table 2.

After the data collection phase, the questionnaires were coded, and the completeness of the data was thoroughly checked to ensure accuracy and consistency. Subsequently, the Likert-scale responses were converted into numerical values for analysis using multipliers commonly used in quality function deployment [92,93,94]. The use of 9 for highly effective, 3 for effective, 1 for limited effectiveness, and 0 for do not know ensures significant distances between highly effective and less effective strategies. The scores were then summed to prioritize the strategies based on their overall effectiveness (Table 3).

3.2.2. Part 2—Interviews

In the second part of the study, we further narrowed down the participants to 34 and conducted semi-structured interviews with the selected participants. During this stage, in-depth discussions were held to explore the strategies further. The participants were asked about the critical factors they consider when implementing strategies to mitigate or eliminate supply chain disruptions. Additionally, insights were gathered regarding which strategies were perceived as the least effective in addressing supply chain and distribution channel disruptions.

3.3. Reflexivity

None of the authors of this study were affiliated with the EPSS. Three team members (A.B., T.G., and U.S.) possess extensive experience and expertise in qualitative research methodology. The interviews were conducted by one of the local authors, A.B. All authors had prior training and a thorough understanding of the study context and values, enabling them to perform transcription and crosscheck the contents during translation. The authors discussed an initial analysis of potential informants and created schedules to conduct the interviews at the participants’ offices.

3.4. Selection of Participants for the Interview

Participants were chosen based on their roles, ensuring a comprehensive representation across all departments within EPSS. Their involvement was contingent on obtaining consent, with efforts made to guarantee their full understanding of the study’s objectives and the confidentiality of their privacy. Emphasis was placed on the voluntary nature of participation, and oral consent was obtained from each participant.

Informed by the findings of the survey (Table 3), the interviews focused on surfacing the types of strategies employed to manage supply disruptions in the pharmaceutical supply chain and distribution channels. Additionally, participants were asked about the most crucial factors considered during the implementation of strategies to reduce or eliminate supply chain disruptions, the identification of strategies that have been least effective in addressing disruptions, the specifics of supply chain management strategies used to tackle disruptions, and an exploration of barriers hindering the success of supply chain management strategies.

After obtaining participants’ consent, in-depth interviews were conducted. Both tape recordings and notes were employed for comprehensive documentation. The researchers facilitated the interviews by posing questions naturally, attentively listening to participants’ responses, and incorporating follow-up questions and probes based on those responses. These interviews took place either face-to-face or online, involving one interviewer and one participant. The choice of interview location was convenient for participants, occurring in their offices or the researcher’s office. Online interviews were conducted in participants’ homes based on their preferences and residences. The demographics of interview participants are summarized in Table 4.

3.5. Ethical Approval

Ethical approval was obtained from Addis Ababa University’s Institutional Review Board and the School of Pharmacy’s Ethics Review Committee (Protocol 010/22/SoP). The EPSS Directors also granted permission. The participants were assured of their right to withdraw and gave written consent. Privacy was maintained, using pseudonyms for interviewees. Records were securely stored.

3.6. Analysis

Data collection and analysis were conducted simultaneously. Interviews were recorded, transcribed, and translated. A line-by-line coding approach yielded 70 codes, which were merged into 9 family codes and then into 4 main themes. Thematic analysis was included to identify and organize central themes. An inductive approach guided further data collection and analysis until theoretical saturation was reached.

4. Results

The survey findings are summarized in Table 2. In part 2, semi-structured interviews informed by the survey provided deeper insights into drug shortages and pharmaceutical supply chain management, identifying four themes detailed below (Figure 1).

Themes 1—Most Successful Strategies Communication and Stock Status Assessment:

Regular central-level stock assessments and hub updates optimize planning and prevent stockouts or overstocking. A participant noted, “Good communication and sharing stock status information with hubs is crucial.” (Participant 8)

Supportive Supervision and Training:

Providing guidance and training to staff minimizes drug shortages and motivates them. A participant stated, “Supportive supervision and training are very helpful for mitigating drug shortages.” (Participant 23)

Streamlining Procurement Processes:

Early tender notifications expedite supply acquisition, reduce lead times, and enhance supply chain responsiveness, despite potential challenges. A respondent remarked, “Early tendering and procurement notification is crucial.” (Participant 17)

Enhancing Supplier Relationship Management:

Collaboration with suppliers and stakeholders improves communication and response coordination during disruptions. A participant emphasized, “Effective supplier relationship management ensures a seamless supply chain.” (Participant 10)

These interconnected strategies—Communication and Stock Status Assessment, Supportive Supervision and Training, Streamlining Procurement Processes, and Enhancing Supplier Relationship Management—demonstrate a holistic and collaborative approach to optimizing pharmaceutical supply chain management.

Theme 2—Least Successful Strategies Used by EPSS Rationing:

Rationing controls pharmaceutical supply allocation to ensure fair distribution during scarcity. Though not as proactive as other strategies, it can help balance supply and demand. However, some participants question its effectiveness, with one stating, “Rationing will not solve the problem; it is just taken as a painkiller.” (Participant 15)

Redistribution:

Redistributing products between hubs can incur high costs and time. Efficient redistribution requires strong communication and coordination. A respondent noted, “Redistribution is costly and time-taking, creating a burden on professionals.” (Participant 29)

Restricted Tenders and Emergency Procurement:

Restricted tenders and emergency procurement can meet immediate needs but disrupt routine practices. This may cause future shortages. One participant highlighted, “Emergency situations make us neglect routine practice, creating another shortage.” (Participant 34)

In summary, while rationing, redistribution, and restricted tenders with emergency procurement are less effective strategies, they can still mitigate shortages temporarily until more proactive methods are implemented. These methods underscore the need for balancing reactive and proactive approaches in pharmaceutical supply chain management.

Theme 3—Key Success Factors Data Quality, Technology, and Automation, Supply Chain Visibility, Demand Forecasting:

Accurate data are crucial for effective supply chain management. Real-time, high-quality data enable informed decisions and prompt responses to disruptions. A participant noted, “Data quality plays a significant role in the whole cycle of supply chain management” (Participant 28). Technology and automation reduce manual errors and enhance efficiency. Transparent supply chain visibility aids in better planning and risk management. Proper demand forecasting minimizes overstocking and stockouts, ensuring a smooth flow of products.

Procurement Lead Time and Supplier Reputation and Relationship Management:

Shortening procurement lead time is critical. Delays can affect the entire supply chain. A respondent said, “Reducing the procurement lead time will have a great impact on the whole supply chain process” (Participant 26). Reliable suppliers are vital for timely deliveries and quality products. Effective supplier management fosters strong relationships. As one participant highlighted, “Managing suppliers is quite important” (Participant 33).

Compliance and Regulatory Considerations, Risk Management Strategies:

Adhering to industry regulations avoids delays and disruptions. Developing risk management strategies specific to the pharmaceutical supply chain is essential. Identifying risks, assessing their impact, and establishing contingency plans enhance resilience. Considering these factors helps organizations proactively address disruptions, leading to a more robust and reliable pharmaceutical supply chain.

Theme 4—Barriers within EPSS for Success Several barriers impede effective supply chain management at EPSS, highlighting logistical and organizational challenges.

Data Quality Problems: Poor data quality due to inaccurate demand reports from health professionals compromises reliability. A respondent noted, “Professionals from health facilities often submit inaccurate demand reports, assuming EPSS won’t fulfill their requested amounts, compromising data quality.” (Participant 22)

Shortage of Hard Currency: Currency shortages delay procurement and disrupt the supply chain. “Even with effective forecasting and tender processes, currency shortages in the country delay EPSS’s ability to procure products on time.” (Participant 19)

Poor Communication within EPSS and Between Hubs: Internal communication gaps worsen shortages. “Poor communication within departments and between central EPSS and hubs exacerbates shortages.” (Participant 11)

Failure of Local Manufacturers and Suppliers to Deliver: Local manufacturers, reliant on imported raw materials, often fail to meet commitments. “Local manufacturers, reliant on global supply chains for raw materials, coupled with low capacity, impact product availability.” (Participant 9)

Bureaucratic Processes and the Bullwhip Effect: Bureaucratic delays and intensified demand fluctuations add complexity.

Addressing these challenges requires improving data quality, streamlining procurement, enhancing communication, investing in human resources, and tailoring procurement laws to the pharmaceutical sector. These measures can lead to a more successful and resilient supply chain system, benefiting both the EPSS and the broader pharmaceutical industry.

5. Discussion

The primary aim of this research was to comprehend the risks within EPSS supply chains and identify strategies for mitigating the risk of drug shortages. Building on the literature review, the study explored various shortage-mitigating strategies through a survey and participant interviews. The findings highlighted successful and less successful strategies, key success factors, and barriers within the EPSS concerning drug shortages. This study’s contributions are twofold. First, it advances our theoretical understanding by exploring proactive and reactive supply chain strategies for mitigating drug shortages within the pharmaceutical supply chain. Second, it sheds light on key success factors crucial for overcoming drug shortages in resource-limited countries, providing practical insights.

The literature review emphasized the dichotomy of proactive and reactive strategies in supply chain risk management. Proactive strategies involve anticipatory and preventive actions to address potential challenges before they occur, while reactive strategies respond to challenges after they have manifested [95]. These strategies include supplier development, supply chain contracts, contingency planning, and disaster management [96]. Studies from various contexts have identified specific strategies such as establishing information systems, imposing public service obligations, influencing trade rules, and forming committees to collaboratively tackle shortages [97]. The EPSS study aligns with these findings, offering insights into the effectiveness of such strategies within a developing country’s pharmaceutical supply chain (Figure 2).

Additionally, the research provides a unique perspective by delving into specific proactive strategies employed by EPSS, such as communication, stock status assessment, supportive supervision and training, and streamlining procurement processes. Resource sharing through strategic alliances was also identified as a proactive resilience strategy [9]. Reactive strategies discussed in the literature, such as safety stock, capacity buffers, and supplier backups, were found to be used in response to uncertainty in the pharmaceutical supply chain [98]. It is important to understand that both proactive and reactive strategies do not stand alone as single entities; they interact with each other. This interaction is illustrated in Figure 2. For instance, data quality, technology, and automation enable better and more frequent communication and stock status assessment, which in turn improves rationing, redistribution, emergency management, compliance, and risk management. The role of data quality, technology, and automation also helps us to easily communicate and address information.

Furthermore, our findings reveal that supportive supervision and training are crucial when dealing with uncertainty of demand and supply, and this was evident in one of the studies conducted by Bilal et al. [19], which emphasized the pivotal role of training in fostering workforce competence and motivation. While short-term training interventions were deemed crucial for immediate skill enhancement, participants emphasized the long-term imperative of elevating the quality of education programs, including degree-level education, in cultivating a pipeline of skilled professionals.

The study adds depth by examining how the EPSS utilizes these strategies to address medicine shortages. Furthermore, the study acknowledges the scarcity of research on supply chain risk management in developing countries. This gap is critical because of the heightened uncertainty in such regions, emphasizing the study’s relevance to a more fragile economic and political structure.

In terms of managerial implications, the study underscores the importance of a responsive supply chain structure for mitigating risks effectively. It highlights the need for a nuanced approach, understanding that certain strategies may not be effective in isolation and that a combination of proactive and reactive strategies may be necessary. Managers are encouraged to focus on key success factors, including data quality, technology, automation, and supply chain visibility while addressing barriers like data quality problems and communication issues. The success of reactive and proactive strategies hinges on their alignment with the company’s overall supply chain goals and the particular uncertainties encountered. Combining both strategies in a balanced manner can create a more resilient supply chain that effectively handles uncertainties. In essence, although reactive and proactive strategies have distinct roles, their interaction is vital for optimal supply chain flexibility. Companies that effectively merge these approaches can boost their responsiveness to uncertainty and advance long-term enhancements in their supply chain design and operations.

While interpreting the findings, it is essential to acknowledge the study’s limitations, including its focus solely on EPSS. The reliance on self-reported data and a relatively small sample size may limit the generalizability of insights. Future research should adopt broader sampling methods to enhance the study’s external validity. In conclusion, despite these limitations, this study provides valuable insights into pharmaceutical supply chain management within EPSS. The identified strategies, success factors, and barriers offer actionable steps for stakeholders to enhance the resilience and efficiency of pharmaceutical supply chains in Ethiopia. The continuous evaluation and adaptation of these strategies are imperative for maintaining a responsive and sustainable pharmaceutical supply chain in the country.

6. Conclusions

This paper has shed light on the proactive and reactive strategies that are important in reducing drug shortages in the Ethiopian pharmaceutical supply chain. By showing how these strategies work together, we emphasize the need to use both for effective mitigation. The distinction between effective and ineffective strategies in this study is a useful guide for supply chain management practitioners. It gives clear insights into areas that need improvement and changes in their current practices. This practical advice is crucial for improving supply chain operations and building resilience against drug shortages.

In conclusion, this paper not only contributes to the existing knowledge by unraveling the dynamics of mitigating drug shortages but also provides a roadmap for future exploration. The intricacies of this study pave the way for further research, encouraging a deeper understanding of how to address and mitigate drug shortages in the complex landscape of resource-limited countries.

Acknowledgments

The authors acknowledge the Kühne Foundation for financially supporting the data collection process. We also extend our gratitude to EPSS staff, especially Kalkidan Endashaw, Mahlet Tibebu, Dagim Ayalew, Yonas Alemu and Haftu Berhe, for their support throughout this study. Our sincere appreciation goes to Andre Kreie and Daniel Zapata for their unwavering support.

Author Contributions

Conceptualization, T.G.F. and U.S.B.; methodology, A.I.B. and U.S.B.; software, A.I.B.; validation, A.I.B., T.G.F. and U.S.B.; formal analysis, A.I.B.; investigation, A.I.B.; resources, T.G.F. and U.S.B.; data curation, A.I.B.; writing—original draft preparation, A.I.B.; writing—review and editing, T.G.F. and U.S.B.; visualization, A.I.B.; supervision, T.G.F. and U.S.B.; project administration, A.I.B.; funding acquisition, T.G.F. and U.S.B. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study has got ethical approval form Addis Ababa University College of Health Sciences Institutional Review Board, with Protocol Number 010/22/SoP.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. As well as written informed consent has been obtained from the participants to publish this paper.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A

Part II: Please indicate by ticking in the box in which you think is right strategies to minimize the drug shortages in EPSS. S.no	Supply chain strategies for management of drug shortages	Highly effective	Effective	Don’t know	Less effective	It will never be effective	
1	To use different forecasting methods depending on the demand characteristics of the pharmaceuticals						
2	Engage in systematic de-bottlenecking (not just focusing on existing bottlenecks, but also identifying future potential bottlenecks (in other words, forecasting them) and addressing them before they materialize or become acute)						
3	Strengthen demand forecasting: (Accurate demand forecasting is essential to prevent stockouts. Analyzing historical consumption data, patient trends, and disease patterns can help forecast future demand for medicines more accurately, enabling proactive procurement and supply management)						
4	Collaborative planning, forecasting and replenishment (CPFR) analysts (CPFR analysts are responsible for analyzing data, coordinating activities, and fostering collaboration among trading partners to improve supply chain performance and achieve common goals)						
5	Market monitoring enhancement” (to identify more rapidly and accurately the market needs and medicine shortages in the country)						
6	Developing detailed guidelines on procurement strategies under a crisis						
7	Improving the procurement lead time						
	Considering multiple suppliers						
8	Selecting drug suppliers with short lead times (The tender process should not only consider the price per unit of drugs from each potential supplier, but also the costs that would be incurred if the supply chain must compensate for longer supplier lead times)						
9	Restriction and quota for those pharmaceuticals with unstable demand						
10	Redistribution of the stock which are excess in some hub and distribute to other hub which have shortage						
11	Minimizing wastage of products						
12	Improve inventory management along supply chains						
13	Time Postponement: This approach involves delaying the delivery or shipping of products until demand patterns become clearer. For example, EPSS may hold off on replenishing inventory at stores until it can assess actual sales data or customer demand.						
14	Implement buffer stock and emergency procurement mechanisms (Having buffer stock or emergency procurement mechanisms in place can help mitigate the risk of stockouts).						
15	Increasing the quantity of the safety stock						
16	Increase communication among stakeholders (Collaboration and coordination among all stakeholders involved in the pharmaceutical supply chain, including government agencies, health facilities, procurement agencies, and suppliers, is crucial to prevent stockouts.)						
17	Establishing feedback loops among stakeholders involved in the forecasting process can facilitate continuous improvement. Regular feedback from health facilities, procurement agencies, and suppliers can help identify areas for improvement and refine forecasting models to prevent stockouts.						
18	Shortage reporting and tracking system (It typically involves a structured approach to reporting and tracking shortages, as well as coordinating efforts to address them in a timely and efficient manner.)						
19	Maintain end-to-end public health supply chain visibility (end-to-end supply chain data access)						
20	Advance notification system when there is shortage						
21	Education and training for the staff on how to handle when there is shortage						
22	Establishing robust supply chain management systems						
23	Fast decision-making (Having high quality and timely information does little good if managers running health care systems are unwilling and unable to respond quickly to that information)						
24	Strengthening access to medicines through public-private partnerships (Collaborating with private sector entities, such as pharmaceutical manufacturers, distributors, and retailers, can help improve the availability of medicines and ensure timely replenishment of stock)						
25	Communicating with the officer who came to purchase and provide what you have in the store for example if the person who came from health facilities came to purchase albendazole tablet and if Albendazole is stock out negotiate to change it in to Mebendazole tablet						
26	The Reorder Level Strategy, also known as a two-bin system (which is technique used to determine when to reorder items that have a predictable demand pattern. A specific quantity of stock is set as the reorder level, which serves as a trigger to reorder more inventory. When the stock level in the active bin reaches the reorder level, it signals that it’s time to reorder to avoid stockouts).						
27	Buy to Order (BTO) strategy also known as Purchase-to-Order, is approach where products are only purchased from suppliers or manufactured in response to specific customer orders. In other words, inventory is not pre-stocked, but instead, products are procured or produced on demand as orders are received						

Figure 1 The main themes and sub-themes of the thematic analysis.

Figure 2 How the different strategies interact to aid improved management of supply chain performance under demand uncertainties.

pharmacy-12-00132-t001_Table 1 Table 1 Supply chain strategies for managing uncertainties.

Supply Chain Strategies for Management of Drug Shortages	References	
Using different forecasting methods	[66]	
Market monitoring enhancement	[67]	
Selecting drug suppliers with short lead times	[68]	
Strengthen demand forecasting	[69,70]	
Improve inventory management along supply chains	[71]	
Implement buffer stock and emergency procurement mechanisms	[37]	
Increasing the quantity of the safety stock	[72]	
Establishing feedback loops among stakeholders involved in the forecasting process	[42]	
Shortage reporting and tracking system	[25,67,73,74,75,76,77]	
Maintain end-to-end public health supply chain visibility	[67]	
Engage in systematic de-bottlenecking	[78]	
Minimizing wastage of products	[25,76,79]	
Strengthening access to medicines through public-private partnerships	[80]	
Increase communication among stakeholders	[34,41,64,67,70,71,74,80,81]	
Advance notification system when there is shortage	[67,74,82]	
Improving the procurement lead time	[74]	
Restriction and quota for those pharmaceuticals with unstable demand	[25]	
Education and training for the staff on how to handle shortages	[25,70,74]	
Establishing robust supply chain management systems	[83]	
Fast decision-making	[42]	
Collaborative planning, forecasting and replenishment (CPFR)	[84,85]	
Developing guidelines on procurement strategies under a crisis	[86,87]	
The Reorder Level Strategy, also known as a two-bin system	[88]	
Communicating with the purchasing officer and provide what you have in the stock	[25,89]	
Time Postponement	[90]	
Buy to Order (BTO) (also known as Purchase-to-Order)	[91]	
Redistribution of the stock	[25]	

pharmacy-12-00132-t002_Table 2 Table 2 Socio demographic profile of respondents in EPSS in 2023.

Socio Demographic Variables	Frequency	Percent	
Gender			
     Female	16	32	
     Male	34	68	
Age in years			
     25–30	16	32	
     30–35	19	38	
Year of experience			
     1–5	16	32	
     Greater than 5	34	68	
Profession			
     Pharmacist	37	74	
     Laboratory	8	16	
     Biomedical engineer	5	10	
Level of education			
     Degree	31	62	
     MSc	19	38	
Current working department			
     Contract management	6	12	
     Quantification market shaping	13	26	
     Tender management	12	24	
     Warehouse inventory management	19	38	

pharmacy-12-00132-t003_Table 3 Table 3 Summary of findings from the survey of supply chain practitioners.

Supply Chain Strategies for Management of Drug Shortages	Highly Effective (x9)	Effective (x3)	Don’t Know (x0)	Less Effective (x − 3)	It Will Never Be Effective (x − 9)	Weighted Score	Rank	
Using different forecasting methods	28 (56%)	15 (30%)	5 (10%)	2 (4%)	0	291	1	
Market monitoring enhancement	27 (54%)	17 (34%)	5 (10%)	1 (2%)	0	291	1	
Selecting drug suppliers with short lead times	19 (38%)	21 (42%)	7 (14%)	3 (6%)	0	225	2	
Strengthen demand forecasting	20 (40%)	17 (34%)	8 (16%)	5 (10%)	0	216	3	
Improve inventory management along supply chains	19 (38%)	20 (40%)	6 (12%)	5 (10%)	0	216	3	
Implement buffer stock and emergency procurement mechanisms	15 (30%)	26 (52%)	9 (18%)	0	0	213	4	
Increasing the quantity of the safety stock	15 (30%)	26 (52%)	6 (12%)	3 (6%)	0	204	5	
Establishing feedback loops among stakeholders involved in the forecasting process.	16 (32%)	23 (46%)	6 (12%)	4 (8%)	0	201	6	
Shortage reporting and tracking system	15 (30%)	24 (48%)	8 (16%)	3 (6%)	0	198	7	
Maintain end-to-end public health supply chain visibility	16 (32%)	21 (42%)	10 (20%)	3 (6%)	0	198	7	
Engage in systematic de-bottlenecking	10 (20%)	36 (72%)	4 (8%)	0	0	198	7	
Minimizing wastage of products	14 (28%)	26 (52%)	7 (14%)	3 (6%)	0	195	8	
Strengthening access to medicines through public-private partnerships	15 (30%)	24 (48%)	4 (8%)	4 (8%)	0	195	8	
Increase communication among stakeholders	17 (34%)	18 (36%)	9 (18%)	6 (12%)	0	189	9	
Advance notification system when there is shortage	16 (32%)	21 (42%)	6 (12%)	6 (12%)	0	189	9	
Improving the procurement lead time	18 (36%)	16 (32%)	12 (24%)	2 (4%)	2 (4%)	186	10	
Restriction and quota for those pharmaceuticals with unstable demand	15 (30%)	19 (38%)	13 (26%)	3 (6%)		183	11	
Education and training for the staff on how to handle when there is shortage	12 (24%)	29 (58%)	4 (8%)	4 (8%)	0	183	11	
Establishing robust supply chain management systems	13 (26%)	23 (46%)	9 (18%)	3 (6%)	0	177	12	
Fast decision-making	12 (24%)	26 (52%)	6 (12%)	4 (8%)	0	174	13	
Collaborative planning, forecasting and replenishment (CPFR)	12 (24%)	26 (52%)	6 (12%)	6 (12%)	0	168	14	
Developing detailed guidelines on procurement strategies under a crisis	11 (22%)	29 (58%)	2 (4%)	8 (16%)		162	15	
The Reorder Level Strategy, also known as a two-bin system	13 (26%)	22 (44%)	5 (10%)	6 (12%)	1 (2%)	156	16	
Communicating with the purchasing officer and provide what you have in the store	16 (32%)	15 (30%)	5 (10%)	9 (18%)	2 (4%)	144	17	
Time Postponement	7 (14%)	28 (56%)	11 (22%)	4 (8%)	0	135	18	
Buy to Order (BTO) (also known as Purchase-to-Order)	11 (22%)	16 (32%)	15 (30%)	5 (10%)	0	132	19	
Redistribution of the stock	13 (26%)	28 (56%)	6 (12%)	3 (6%)	9	111	20	

pharmacy-12-00132-t004_Table 4 Table 4 Interview participant profile.

Socio Demographic Variables	Frequency	Percent	
Gender			
     Female	14	41.17%	
     Male	20	58.82%	
Age in years			
     25–30	12	35.29%	
     30–35	14	41.17%	
     Greater than 35	8	23.52%	
Year of experience			
     1–5	16	32%	
     Greater than 5	34	68%	
Profession			
     Pharmacist	26	76.47%	
     Laboratory	4	11.76%	
     Biomedical engineer	4	11.76%	
Level of education			
     Degree	22	64.70%	
     MSc	12	35.30%	
Current working department			
     Contract management	4	11.76%	
     Quantification market shaping	10	29.41%	
     Tender management	8	23.52%	
     Warehouse inventory management	10	29.41%	

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Quick J.D. Essential medicines twenty-five years on: Closing the access gap Health Policy Plan. 2003 18 1 3 10.1093/heapol/18.1.1 12582103
2. World Health Organization Annual Report 2003: Essential Drugs and Medicines Policy (No. WHO/EDM/2004.1) World Health Organization Geneva, Switzerland 2004
3. World Health Organization WHO Medicines Strategy 2004–2007: Countries at the Core (No. WHO/EDM/2004.5) World Health Organization Geneva, Switzerland 2004
4. Droti B. O’Neill K.P. Mathai M. Dovlo D.Y.T. Robertson J. Poor availability of essential medicines for women and children threatens progress towards Sustainable Development Goal 3 in Africa BMJ Glob. Health 2019 4 (Suppl. S9) e001306 10.1136/bmjgh-2018-001306 31673436
5. Kaakeh R. Sweet B.V. Reilly C. Bush C. DeLoach S. Higgins B. Clark A.M. Stevenson J. Impact of drug shortages on US health systems Am. J. Health-Syst. Pharm. 2011 68 1811 1819 10.2146/ajhp110210 21930639
6. GAO GAO-16-595: Drug Shortages: Certain Factors are Strongly Associated with This Persistent Public Health Challenge (July) GAO Washington, DC, USA 2016
7. Alspach J.G. Is the drug shortage affecting patient care in your critical care unit? Crit. Care Nurse 2012 32 8 13 10.4037/ccn2012810
8. Tucker E. Modeling Pharmaceutical Supply Chains to Mitigate Drug Shortages Ph.D. Thesis University of Michigan Ann Arbor, MI, USA 2020
9. Vann Yaroson E. Breen L. Hou J. Sowter J. Examining the impact of resilience strategies in mitigating medicine shortages in the United Kingdom’s (UK) pharmaceutical supply chain (PSC) Benchmarking Int. J. 2024 31 683 706 10.1108/BIJ-07-2022-0460
10. Uthayakumar R. Priyan S. Permissible delay in payments in the two-echelon inventory system with controllable setup cost and lead time under service level constraint Int. J. Inf. Manag. Sci. 2013 24 193 211
11. Jagtap S. Trollman H. Trollman F. Garcia-Garcia G. Parra-López C. Duong L. Martindale W. Munekata P.E.S. Lorenzo J.M. Hdaifeh A. The Russia-Ukraine conflict: Its implications for the global food supply chains Foods 2022 11 2098 10.3390/foods11142098 35885340
12. Attinasi M.G. Balatti M. Mancini M. Metelli L. Supply chain disruptions and the effects on the global economy Econ. Bull. Boxes 2022 8 Available online: https://www.ecb.europa.eu/press/economic-bulletin/focus/2022/html/ecb.ebbox202108_01~e8ceebe51f.en.html (accessed on 15 March 2024)
13. Özkanlısoy Ö. Akkartal E. Digital transformation in supply chains: Current applications, contributions and challenges Bus. Manag. Stud. Int. J. 2021 9 32 55 10.15295/bmij.v9i1.1673
14. Kent P. Haralambides H. A perfect storm or an imperfect supply chain? The US supply chain crisis Marit. Econ. Logist. 2022 24 1 8 10.1057/s41278-022-00221-1
15. Wu X. Zhang C. Du W. An analysis on the crisis of “chips shortage” in automobile industry—Based on the double influence of COVID-19 and trade Friction J. Phys. Conf. Ser. 2021 1971 012100 10.1088/1742-6596/1971/1/012100
16. Boston W. Ukraine war plunges auto makers into new supply-chain crisis Wall Str. J. 2022 Available online: https://www.wsj.com/articles/ukraine-war-plunges-auto-makers-into-new-supply-chain-crisis-11646309152 (accessed on 5 March 2024)
17. Becker T. Supply chain strategies in the VUCA world J. Supply Chain Manag. Logist. Procure 2023 5 372 389 10.69554/XWVP7444
18. Perez-Franco R. Rethinking Your Supply Chain Strategy: A Brief Guide MIT Center for Transportation and Logistics 77 Massachusetts Ave Cambridge, MA, USA 2016 Available online: https://ctl.mit.edu/sites/default/files/RPF2014.pdf (accessed on 5 March 2024)
19. Bilal A.I. Bititci U.S. Fenta T.G. Challenges and the Way Forward in Demand-Forecasting Practices within the Ethiopian Public Pharmaceutical Supply Chain Pharmacy 2024 12 86 10.3390/pharmacy12030086 38921962
20. McLaughlin M. Kotis D. Thomson K. Harrison M. Fennessy G. Postelnick M. Scheetz M.H. Effects on patient care caused by drug shortages: A survey J. Manag. Care Pharm. 2013 19 783 788 10.18553/jmcp.2013.19.9.783 24156647
21. Souliotis K. Papageorgiou M. Politi A. Ioakeimidis D. Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: The unseen impact of the fiscal crisis—The Health Outcomes Patient Environment (HOPE) study Rheumatol. Int. 2014 34 25 33 10.1007/s00296-013-2866-1 24057144
22. Yang C. Wu L. Cai W. Zhu W. Shen Q. Li Z. Fang Y. Current situation, determinants, and solutions to drug shortages in Shaanxi Province, China: A qualitative study PLoS ONE 2016 11 e0165183 10.1371/journal.pone.0165183 27780218
23. AlRuthia Y.S. AlKofide H. AlAjmi R.H. Balkhi B. Alghamdi A. AlNasser A. Alayed A. Alshammari M. Alsuhaibani D. Alathbah A. Drug shortages in large hospitals in Riyadh: A cross-sectional study Ann. Saudi Med. 2017 37 375 385 10.5144/0256-4947.2017.375 28988252
24. Simchi-Levi D. Wang T. Wei Y. Non-anticipativity and dynamic assortment planning Oper. Res. 2014 62 1359 1368
25. Shukar S. Zahoor F. Hayat K. Saeed A. Gillani A.H. Omer S. Hu S. Babar Z.U. Fang Y. Yang C. Drug shortage: Causes, impact, and mitigation strategies Front. Pharmacol. 2021 12 693426 10.3389/fphar.2021.693426 34305603
26. Ghabak V. Seetharaman A. Integration of Machine Learning in Agile Supply Chain Management Proceedings of the 2023 15th International Conference on Computer and Automation Engineering (ICCAE) Sydney, Australia 3–5 March 2023 6 12
27. Begen M.A. Pun H. Yan X. Supply and demand uncertainty reduction efforts and cost comparison Int. J. Prod. Econ. 2016 180 125 134 10.1016/j.ijpe.2016.07.013
28. Hofstra N. Spiliotopoulou E. de Leeuw S. Ordering decisions under supply uncertainty and inventory record inaccuracy: An experimental investigation Decis. Sci. 2024 55 303 318 10.1111/deci.12564
29. Fisher M. What Is the Right Supply Chain for Your Product Harv. Bus. Rev. 1997 75 105 116
30. Lee H.L. Aligning supply chain strategies with product uncertainties Calif. Manag. Rev. 2002 44 105 119 10.2307/41166135
31. Haileselassie W. Mulugeta T. Tigeneh W. Kaba M. Labisso W.L. The situation of cancer treatment in Ethiopia: Challenges and opportunities J. Cancer Prev. 2019 24 33 10.15430/JCP.2019.24.1.33 30993093
32. Carasso B.S. Lagarde M. Tesfaye A. Palmer N. Availability of essential medicines in Ethiopia: An efficiency-equity trade-off? Trop. Med. Int. Health 2009 14 1394 1400 10.1111/j.1365-3156.2009.02383.x 19754520
33. Tewuhibo D. Asmamaw G. Ayenew W. Availability of essential Medicines in Ethiopia: A systematic review J. Community Med. Health Care 2021 6 1049
34. Schwartzberg E. Ainbinder D. Vishkauzan A. Gamzu R. Drug Shortages in Israel: Regulatory Perspectives, Challenges and Solutions Isr. J. Health Pol. Res. 2017 6 17 10.1186/s13584-017-0140-9
35. Besancon L. Chaar B. International Pharmaceutical Federation (FIP): Report of the International Summit on Medicines Shortage; 2013 Available online: https://www.fip.org/files/fip/publications/FIP_Summit_on_Medicines_Shortage.pdf (accessed on 5 March 2024)
36. Barbosa-Povoa A.P. Jenzer H. De Miranda J.L. Pharmaceutical Supply Chains-Medicines Shortages Springer International Publishing Cham, Switzerland 2019
37. Fox E.R. Sweet B.V. Jensen V. Drug shortages: A complex health care crisis Mayo Clinic Proceedings Elsevier Amsterdam, The Netherlands 2014 Volume 89 No. 3 361 373
38. Babar Z.U.D. Forming a medicines pricing policy for low and middle-income countries (LMICs): The case for Pakistan J. Pharm. Policy Pract. 2022 15 9 10.1186/s40545-022-00413-3 35209945
39. EAHP 2019 EAHP Medicines Shortages Report: Medicines Shortages in European Hospitals: Medicines Shortages in the Hospital Sector—Prevalence, Nature and Impact on Patient Care EAHP Copenhagen, Denmark 2019 Available online: https://www.eahp.eu/sites/default/files/eahp_2019_medicines_shortages_report.pdf (accessed on 5 March 2024)
40. Eshetu G. Gebena T. 2020 Challenges of Pharmaceutical Supply Chain Management. In Public Health Facilities Facilities Inwestshewa Zone, Oromia Region-Ethiopia Available online: https://etd.aau.edu.et/server/api/core/bitstreams/621f06bf-3244-4c15-9dbc-45e4e471d714/content (accessed on 5 March 2024)
41. Fox E.R. Tyler L.S. Managing drug shortages: Seven years’ experience at one health system Am. J. Health-Syst. Pharm. 2003 60 245 253 10.1093/ajhp/60.3.245 12613233
42. Fox E.R. McLaughlin M.M. ASHP guidelines on managing drug product shortages Am. J. Health-Syst. Pharm. 2018 75 1742 1750 10.2146/ajhp180441 30061155
43. WHO Medicines Shortages in Europe WHO Regional Office for Europe Copenhagen, Denmark 2017
44. Heiskanen K. Ahonen R. Kanerva R. Karttunen P. Timonen J. The reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland PLoS ONE 2017 12 e0179479 10.1371/journal.pone.0179479 28658307
45. Hendricks K.B. Singhal V.R. Supply Chain Disruptions and Corporate Performance Supply Chain Disruptions: Theory and Practice of Managing Risk Gurnani H. Mehrotra A. Ray S. Springer London, UK 2012
46. Christopher M. Logistics & Supply Chain Management 4th ed. Pearson Edinburgh, UK 2011
47. Zsidisin G.A. A grounded definition of supply risk J. Purch. Supply Manag. 2003 9 217 224 10.1016/j.pursup.2003.07.002
48. Jüttner U. Peck H. Cristopher M. Supply Chain Risk Management: Outlining an Agenda for Future Research Int. J. Logist. 2003 6 197 210 10.1080/13675560310001627016
49. Christopher M. Lee H. Mitigating supply chain risk through improved confidence Int. J. Phys. Distrib. Logist. Manag. 2004 34 388 396 10.1108/09600030410545436
50. Kefale A.T. Shebo H.H. Availability of essential medicines and pharmaceutical inventory management practice at health centers of Adama town, Ethiopia BMC Health Serv. Res. 2019 19 254 10.1186/s12913-019-4087-0 31023314
51. Hallikas J. Karvonen I. Pulkkinen U. Virolainen V.M. Risk analysis and assessment in network environments: A dyadic case study Int. J. Prod. Econ. 2004 90 27 38 10.1016/S0925-5273(01)00098-6
52. Harland C. Brenchley R. Walker H. Risk in supply networks J. Purch. Supply Manag. 2003 9 51 62 10.1016/S1478-4092(03)00004-9
53. Kleindorfer P.R. Saad G.H. Managing disruption risks in supply chains Prod. Oper. Manag. 2005 14 53 68 10.1111/j.1937-5956.2005.tb00009.x
54. Zsidisin G.A. Henke M. Revisiting Supply Chain Risk Springer Cham, Switzerland 2019 Volume 7
55. Johnson M.E. Learning from Toys: Lessons in Managing Supply Chain Risk from the Toy Industry Calif. Manag. Rev. 2001 43 106 124 10.2307/41166091
56. Chopra S. Sodhi M.S. Managing risk to avoid supply-chain breakdown MIT Sloan Manag. Rev. 2004 Available online: https://sloanreview.mit.edu/article/managing-risk-to-avoid-supplychain-breakdown/ (accessed on 5 March 2024)
57. USAID|DELIVER PROJECT Health Logistics in Tanzania: Timeline of Accomplishments for Supply Chain Interventions Arlington VA. 2016 Available online: https://deliver.jsi.com/wp-content/uploads/2016/12/FinaCounRepo_TZ.pdf (accessed on 8 March 2020)
58. Federal Ministry of Health National Pharmacy Service, Pharmaceuticals Supply Chain, and Medical Device Management Monitoring and Evaluation Framework Addis Ababa. 2019 Available online: http://repository.iifphc.org/bitstream/handle/123456789/526/National%20Pharmacy%20Service%2c%20Pharmaceuticals%20Supply%20Cain%20and%20Media%20Equipment%20Managment%20Monitering%20and%20Evaluation%20Framework.pdf?seqence=1&isAllowed=y (accessed on 12 March 2024)
59. Nfor E. Maxim L. Gbaguidi A. Levenger M. Conesa S. Benin National Supply Chain Assessment Management Sciences for Health Arlington, VA, USA 2016
60. Boche B. Mulugeta T. Gudeta T. Procurement Practice of Program Drugs and Its Challenges at the Ethiopian Pharmaceuticals Supply Agency: A Mixed Methods Study INQUIRY J. Health Care Organ. Provis. Financ. 2022 59 00469580221078514 10.1177/00469580221078514
61. The Federal Democratic Republic of Ethiopia Pharmaceuticals Supply Transformation Plan II (PSTP II) 2020/21-2029/30 Final Report 2020 Available online: https://epss.gov.et/wp-content/uploads/2022/06/PSTP-II-fina-ASK..pdf (accessed on 5 March 2024)
62. Shah N.H. LePendu P. Bauer-Mehren A. Ghebremariam Y.T. Iyer S.V. Marcus J. Nead K.T. Cooke J.P. Leeper N.J. Proton pump inhibitor usage and the risk of myocardial infarction in the general population PLoS ONE 2015 10 e0124653 10.1371/journal.pone.0124653 26061035
63. Laínez J.M. Schaefer E. Reklaitis G.V. Challenges and opportunities in enterprise-wide optimization in the pharmaceutical industry Comput. Chem. Eng. 2012 47 19 28 10.1016/j.compchemeng.2012.07.002
64. Costelloe E.M. Guinane M. Nugent F. Halley O. Parsons C. An audit of drug shortages in a community pharmacy practice Ir. J. Med. Sci. (1971-) 2015 184 435 440 10.1007/s11845-014-1139-7
65. Feitzinger E. Lee H.L. Mass customization at Hewlett Packard: The power of postponement Harv. Bus. Rev. 1997 75 116 122 10174793
66. Kolass S. Rostami-Tabar B. Siemsen E. Demand Forecasting for Executives and Professionals CRC Press Boca Raton, FL, USA 2023
67. US Food and Drug Administration Center for Drug Evaluation and Research Office of New Drugs, Drug Shortage Management. Manual of Policies and Procedures. 2012 Available online: https://www.fda.gov/media/72447/download (accessed on 5 March 2024)
68. Tomlin B. On the value of mitigation and contingency strategies for managing supply chain disruption risks Manag. Sci. 2006 52 639 657 10.1287/mnsc.1060.0515
69. Malik M. Hassali M.A. Shafie A.A. Hussain A. Why hospital pharmacists have failed to manage antimalarial drugs stock-outs in Pakistan? A qualitative insight Malar. Res. Treat. 2013 2013 342843 10.1155/2013/342843 24223321
70. Walker J. Chaar B.B. Vera N. Pillai A.S. Lim J.S. Bero L. Moles R.J. Medicine shortages in Fiji: A qualitative exploration of stakeholders’ views PLoS ONE 2017 12 e0178429 10.1371/journal.pone.0178429 28582409
71. Hedman L. Global approaches to addressing shortages of essential medicines in health systems WHO Drug Inf. 2016 30 180
72. Chen E. Goold S. Harrison S. Ali I. Makki I. Kent S.S. Shuman A.G. Drug shortage management: A qualitative assessment of a collaborative approach PLoS ONE 2021 16 e0243870 10.1371/journal.pone.0243870 33891609
73. Giammona R. Di Martino E. Vinci D.L. Provenzani A. Polidori P. 5PSQ-096 Hazard vulnerability analysis to evaluate the risk of drug shortages according to therapeutic class BMJ 2020 27 10.1136/ejhpharm-2020-eahpconf.413
74. Dill S. Ahn J. Drug shortages in developed countries—Reasons, therapeutic consequences, and handling Eur. J. Clin. Pharmacol. 2014 70 1405 1412 10.1007/s00228-014-1747-1 25228250
75. Said A. Goebel R. Ganso M. Zagermann-Muncke P. Schulz M. Drug shortages may compromise patient safety: Results of a survey of the reference pharmacies of the Drug Commission of German Pharmacists Health Policy 2018 122 1302 1309 10.1016/j.healthpol.2018.09.005 30337159
76. Mazer-Amirshahi M. Pourmand A. Singer S. Pines J.M. van den Anker J. Critical drug shortages: Implications for emergency medicine Acad. Emerg. Med. 2014 21 704 711 10.1111/acem.12389 25039558
77. Quilty S. Medicines shortages in Australia—The reality Australas. Med. J. 2014 7 240 10.4066/AMJ.2014.1933 25031644
78. AlAzmi A. AlRashidi F. Medication Exchange and Sharing Network Program (MESNP) initiative to cope with drug shortages in the Kingdom of Saudi Arabia (KSA) Risk Manag. Healthc. Policy 2019 12 115 121 10.2147/RMHP.S198375 31372073
79. Rowe W.B. Morgan B. Whitehurst R. Bush P.A. Increasing Medication Access by Promoting Appropriate Use of Multi-Dose Vials Plast. Aesthetic Nurs. 2020 40 177 182 10.1097/PSN.0000000000000323
80. Jensen J. A review of public–private partnership activities in health system strengthening The Role of Public-Private Partnerships in Health Systems Strengthening: Workshop Summary National Academies Press (US) Cambridge, MA, USA 2016
81. Nixon H.C. Drug shortages in obstetrics Curr. Anesthesiol. Rep. 2021 11 28 36 10.1007/s40140-020-00431-4
82. Tan Y.X. Moles R.J. Chaar B.B. Medicine shortages in Australia: Causes, impact and management strategies in the community setting Int. J. Clin. Pharm. 2016 38 1133 1141 10.1007/s11096-016-0342-1 27383246
83. The International Society for Pharmaceutical Engineering (ISPE) 2013 Available online: https://ispe.org/sites/default/files/initiatives/drug-shortages/2013-ISPE-drug-shortages-survey-questions.pdf (accessed on 5 March 2024)
84. Barratt M. Oliveira A. Supply chain collaboration: Exploring the early initiatives—Part one Supply Chain. Pract. 2001 3 34 47
85. Hill C.A. Zhang G.P. Miller K.E. Collaborative planning, forecasting, and replenishment & firm performance: An empirical evaluation Int. J. Prod. Econ. 2018 196 12 23
86. World Bank: Procurement in Crisis Situations Available online: https://www.worldbank.org/en/topic/procurement/brief/procurement-in-crisis-situations (accessed on 3 January 2024)
87. United Nations Office for Project Services (UNOPS): Emergency Procurement Available online: https://www.unops.org/what-we-do/emergency-procurement (accessed on 3 January 2024)
88. Rosales C.R. Magazine M. Rao U. The 2Bin system for controlling medical supplies at point-of-use Eur. J. Oper. Res. 2015 243 271 280 10.1016/j.ejor.2014.10.041
89. Panic G. Yao X. Gregory P. Austin Z. How do community pharmacies in Ontario manage drug shortage problems? Results of an exploratory qualitative study Can. Pharm. J./Rev. Pharm. Can. 2020 153 371 377 10.1177/1715163520958023
90. Cheng T.E. Li J. Wan C.J. Wang S. Postponement Strategies in Supply Chain Management Springer New York, NY, USA 2010
91. Gunasekaran A. Ngai E.W. Build-to-order supply chain management: A literature review and framework for development J. Oper. Manag. 2005 23 423 451 10.1016/j.jom.2004.10.005
92. American Supplier Institute Quality Function Deployment (Service QFD): 3-Day Workshop ASI Press Dearborn, MI, USA 1994
93. Cohen L. Quality Function Deployment: How to Make QFD Work for You Addison-Wesley Reading, MA, USA 1995
94. Belhe U. Kusiak A. The House of Quality in a Design Process Int. J. Prod. Res. 1996 34 2119 2131 10.1080/00207549608905017
95. Zsidisin G.A. Ritchie B. Supply Chain Risk: A Handbook of Assessment, Management, and Performance Springer Science & Business Media Berlin/Heidelberg, Germany 2008 Volume 124
96. Ghadge A. Dani S. Kalawsky R. Supply chain risk management: Present and future scope Int. J. Logist. Manag. 2012 23 313 339 10.1108/09574091211289200
97. Bochenek T. Abilova V. Alkan A. Asanin B. de Miguel Beriain I. Besovic Z. Bonanno P.V. Bucsics A. Davidescu M. De Weerdt E. Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries Front. Pharmacol. 2018 8 942 10.3389/fphar.2017.00942 29403372
98. Van Kampen T.J. van Donk D.P. van der Zee D.-J. Safety stock or safety lead time: Coping with unreliability in demand and supply Int. J. Prod. Res. 2010 48 7463 7481 10.1080/00207540903348346
